A Multi-centre Study to Assess the Long-term Performance of the Silent Hip™ in Primary Total Hip Replacement Surgery

May 25, 2016 updated by: DePuy International

A Multi-centre, Prospective, Uncontrolled Post Market Clinical Follow-up Study (PMCFS) to Monitor the Survival and Performance of the Silent™ Hip in Subjects Requiring a Total Hip Replacement

The purpose of this study is to monitor the performance and of the Silent Hip™ in the treatment of patients with hip joint disease requiring a total hip replacement. Patients who enter the study will be evaluated at regular intervals following hip surgery using patient, clinical and x-ray assessments.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Terminated

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
89

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Denmark
      • Sønderborg, Denmark
        • Sygehus Sønderjyllands
  • Germany
      • Speyer, Germany
        • Orthopädie Kupfalz
  • Italy
      • Rome, Italy
        • Orthopaedic Clinic University La Sapienza
  • Spain
      • Sevilla, Spain
        • Hospital Nisa Sevilla-Aljarafe
      • Sevilla, Spain
        • Hospital San Juan de Dios del Aljarafe
      • Sevilla, Spain
        • Hospital Santa Ángela De La Cruz
  • United Kingdom
    • Essex
      • Harlow, Essex, United Kingdom
        • Princess Alexandra Hospital
    • Hertfordshire
      • Sawbridgeworth, Hertfordshire, United Kingdom
        • The Rivers Hospital
    • Lancashire
      • Wrightington, Lancashire, United Kingdom, WN6 9EP
        • Wrightington Hospital

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

No older than 65 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Any subject deemed suitable to receive the Silent™ Hip in combination with the Pinnacle™ acetabular cup system, in accordance with all applicable Instructions For Use, should be considered for entry into this study.

Exclusion Criteria:

  • Subjects who, in the opinion of the Investigator, have an existing condition/co-morbidity or infection that would compromise their long-term participation and follow-up in this study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: N/A
  • Interventional Model: Single Group Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
Other: Silent™ Hip
A short cementless, femoral component for use in total hip arthroplasty
Device: Silent™ Hip
A short cementless, femoral component for use in total hip arthroplasty

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Time Frame
Kaplan-Meier survivorship
Time Frame: 5 years post-surgery
5 years post-surgery

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Time Frame
Oxford Hip Score
Time Frame: 6 weeks-6 mths
6 weeks-6 mths
University of California Los Angeles (UCLA) Activity Score
Time Frame: 6 weeks-6 mths
6 weeks-6 mths
EuroQol EQ-5D
Time Frame: 6 weeks-6 mths
6 weeks-6 mths
Harris Hip Score
Time Frame: 6 weeks-6 mths
6 weeks-6 mths
Radiographic analysis
Time Frame: pre-discharge
pre-discharge
Oxford Hip Score
Time Frame: 2 years
2 years
Oxford Hip Score
Time Frame: 3 years
3 years
Oxford Hip Score
Time Frame: 4 Years
4 Years
Oxford Hip Score
Time Frame: 5 years
5 years
Oxford Hip Score
Time Frame: 6 Years
6 Years
Oxford Hip Score
Time Frame: 7 Years
7 Years
Oxford Hip Score
Time Frame: 8 Years
8 Years
Oxford Hip Score
Time Frame: 9 years
9 years
Oxford Hip Score
Time Frame: 10 Years
10 Years
Oxford Hip Score
Time Frame: 11 Years
11 Years
Oxford Hip Score
Time Frame: 12 Years
12 Years
Oxford Hip Score
Time Frame: 13 Years
13 Years
Oxford Hip Score
Time Frame: 14 Years
14 Years
Oxford Hip Score
Time Frame: 15 Years
15 Years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 2 years
2 years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 3 years
3 years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 4 Years
4 Years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 5 Years
5 Years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 6 Years
6 Years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 7 Years
7 Years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 8 Years
8 Years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 9 years
9 years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 10 Years
10 Years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 11 Years
11 Years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 12 Years
12 Years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 13 Years
13 Years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 14 Years
14 Years
University of California Los Angeles (UCLA) Activity Score
Time Frame: 15 years
15 years
EuroQol EQ-5D
Time Frame: 2 Years
2 Years
EuroQol EQ-5D
Time Frame: 3 Years
3 Years
EuroQol EQ-5D
Time Frame: 4 Years
4 Years
EuroQol EQ-5D
Time Frame: 5 Years
5 Years
EuroQol EQ-5D
Time Frame: 6 years
6 years
EuroQol EQ-5D
Time Frame: 7 years
7 years
EuroQol EQ-5D
Time Frame: 8 Years
8 Years
EuroQol EQ-5D
Time Frame: 9 Years
9 Years
EuroQol EQ-5D
Time Frame: 10 Years
10 Years
EuroQol EQ-5D
Time Frame: 11 Years
11 Years
EuroQol EQ-5D
Time Frame: 12 Years
12 Years
EuroQol EQ-5D
Time Frame: 13 Years
13 Years
EuroQol EQ-5D
Time Frame: 14 Years
14 Years
EuroQol EQ-5D
Time Frame: 15 Years
15 Years
Harris Hip Score
Time Frame: 2 Years
2 Years
Harris Hip Score
Time Frame: 5 Years
5 Years
Harris Hip Score
Time Frame: 10 Years
10 Years
Harris Hip Score
Time Frame: 15 Years
15 Years
Radiographic analysis
Time Frame: 6 weeks - 6 mths
6 weeks - 6 mths
Radiographic analysis
Time Frame: 1 year
1 year
Radiographic analysis
Time Frame: 2 Years
2 Years
Radiographic analysis
Time Frame: 5 Years
5 Years
Radiographic analysis
Time Frame: 10 years
10 years
Radiographic analysis
Time Frame: 15 Years
15 Years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
DePuy International

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
January 1, 2011

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
July 1, 2013

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
July 1, 2015

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
June 27, 2011

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
June 27, 2011

First Posted (Estimate)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
June 28, 2011

Study Record Updates

Last Update Posted (Estimate)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
May 27, 2016

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
May 25, 2016

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
August 1, 2014

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • CT09/02

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings